Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL8858431 | 0.98 | ACACB (0.41) | ACACBACACAGABRR1CYP1A2FOLH1 | |
| Ammonia Solution, Strong SCHEMBL8858432 | 0.98 | ACACB (0.41) | ACACBACACAGABRR1CYP1A2FOLH1 | |
| Tetramethylammonium Ion SCHEMBL8858456 | 0.93 | ACACB (0.38) | ACACBACACAGABRR1CYP1A2FOLH1 | |
| SCHEMBL28552427 | 0.81 | ACACB (0.41) | ACACBACACATP53ALDH1A1TSHR | |
| SCHEMBL24759949 | 0.80 | ACACB (0.37) | ACACBACACAGABRR1CYP1A2FOLH1 | |
| SCHEMBL24759951 | 0.80 | ACACB (0.33) | ACACBACACAGABRR1CYP1A2 | |
| SCHEMBL16749901 | 0.79 | GABRR1 (0.44) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL5539684 | 0.79 | GABRR1 (0.44) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL301722 | 0.79 | ACACB (0.40) | ACACBACACAALDH1A1TSHRACLY | |
| SCHEMBL250969 | 0.79 | GABRR1 (0.44) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486416-B2 | Aqueous ink, ink cartridge and ink jet recording method | CANON KABUSHIKI KAISHA (JP) | 2025-12-02 | — | — | US | disclosed |
| US-12023553-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230374216-A1 | COPOLYAMIDE COMPOSITIONS WITH REDUCED CRYSTALLIZATION RATES | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11787940-B2 | Nylon terpolymers | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11753504-B2 | Copolyamide compositions with reduced crystallization rates | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230039150-A1 | AQUEOUS INK, INK CARTRIDGE AND INK JET RECORDING METHOD | CANON KABUSHIKI KAISHA (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20220355164-A1 | GOLF BALL | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2022-11-10 | — | — | US | disclosed |
| US-20220325103-A1 | Nylon Terpolymers | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11384242-B2 | Nylon terpolymers | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2022-07-12 | — | — | US | disclosed |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| WO-2010144446-A1 | (S) -2-BENZYL-3- ( (3R, 4R) -4- (3 -CARBAMO YLPHENYL) -3, 4-DIMETHYLPIPERIDINYL) PROPANOIC ACID AND SALT THEROF AS ANTAGONISTS OF THE OPIOID RECEPTORS | ADOLOR CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009149058-A2 | MODIFIED RELEASE NIACIN FORMULATIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-12-10 | — | — | WO | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| US-20080152660-A1 | Anti-Angiogenic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
| EP-1003900-B1 | A PROCESS FOR THE PREPARATION OF A TERTIARY PERESTER | AKZO NOBEL NV (NL) | 2002-10-02 | — | — | EP | disclosed |
| US-6326372-B1 | BENIGN PROSTATE HYPERPLASIA | MERCK & CO., INC. | 2001-12-04 | — | — | US | disclosed |
| US-6268523-B1 | CONTACTING ACYL COMPOUND WITH TERTIARY HYDROPEROXIDE IN PRESENCE OF ENZYME CATALYST TO PRODUCE PERESTER | AKZO NOBEL NV (NL) | 2001-07-31 | — | — | US | disclosed |
| EP-1003900-A1 | A PROCESS FOR THE PREPARATION OF A TERTIARY PERESTER | Akzo Nobel N.V. (NL) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999005305-A1 | A PROCESS FOR THE PREPARATION OF A TERTIARY PERESTER | AKZO NOBEL N.V. (NL) | 1999-02-04 | — | — | WO | disclosed |
| US-4451665-A | Process for dimerizing acrylates and methacrylates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | ACACB 1700/4885ACACA 1145/4885GABRR1 353/4885 |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | NTSR1, NTSR2, TAAR1 | ACACB 3644/4885ACACA 3067/4885GABRR1 723/4885 |
| US-20080152660-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, KDR | ACACB 596/4885ACACA 754/4885GABRR1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.